Compile Data Set for Download or QSAR

Found 213 hits with Last Name = 'edwards' and Initial = 'r'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226415 (CHEMBL3142312) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 Show InChI InChI=1S/C57H87N15O10S2/c1-4-82-38-24-22-35(23-25-38)29-41-50(77)69-42(28-34-14-6-5-7-15-34)52(79)72-47(33(2)3)54(81)70-43(30-45(58)73)51(78)71-44(32-83-84-57(31-46(74)66-41,36-16-8-9-17-36)37-18-10-11-19-37)53(80)68-40(21-13-27-65-56(62)63)49(76)67-39(48(59)75)20-12-26-64-55(60)61/h5-7,14-15,22-25,33,36-37,39-44,47H,4,8-13,16-21,26-32H2,1-3H3,(H2,58,73)(H2,59,75)(H,66,74)(H,67,76)(H,68,80)(H,69,77)(H,70,81)(H,71,78)(H,72,79)(H4,60,61,64)(H4,62,63,65)/t39-,40-,41+,42+,43+,44+,47+/m1/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.880	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Oxytocin receptor (Homo sapiens (Human))	BDBM50372608 (CHEMBL429736 | GSK-221149A) Show SMILES CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)c2coc(C)n2)C(=O)[C@H](NC1=O)C1Cc2ccccc2C1 Show InChI InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE PC cid PC sid PDB UniChem Similars	PDB Article PubMed	1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Research and Development Curated by ChEMBL					Assay Description Binding affinity to human oxytocin receptor				Bioorg Med Chem Lett 18: 90-4 (2008) Article DOI: 10.1016/j.bmcl.2007.11.008 BindingDB Entry DOI: 10.7270/Q2XD12H2
					More data for this Ligand-Target Pair				3D Structure (crystal)
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414549 (CHEMBL563480) Show SMILES CCN1CCOc2ccc(cc12)C(=O)Nc1nnc(s1)-c1c(Cl)cccc1Cl Show InChI InChI=1S/C19H16Cl2N4O2S/c1-2-25-8-9-27-15-7-6-11(10-14(15)25)17(26)22-19-24-23-18(28-19)16-12(20)4-3-5-13(16)21/h3-7,10H,2,8-9H2,1H3,(H,22,24,26)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	1.26	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414547 (CHEMBL558644) Show SMILES CN1CCOc2ccc(cc12)C(=O)Nc1nnc(s1)-c1c(Cl)cccc1Cl Show InChI InChI=1S/C18H14Cl2N4O2S/c1-24-7-8-26-14-6-5-10(9-13(14)24)16(25)21-18-23-22-17(27-18)15-11(19)3-2-4-12(15)20/h2-6,9H,7-8H2,1H3,(H,21,23,25)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	1.26	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226410 (CHEMBL3142318) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 |r| Show InChI InChI=1S/C57H87N15O10S2/c1-4-82-38-24-22-35(23-25-38)29-41-50(77)69-42(28-34-14-6-5-7-15-34)52(79)72-47(33(2)3)54(81)70-43(30-45(58)73)51(78)71-44(32-83-84-57(31-46(74)66-41,36-16-8-9-17-36)37-18-10-11-19-37)53(80)68-40(21-13-27-65-56(62)63)49(76)67-39(48(59)75)20-12-26-64-55(60)61/h5-7,14-15,22-25,33,36-37,39-44,47H,4,8-13,16-21,26-32H2,1-3H3,(H2,58,73)(H2,59,75)(H,66,74)(H,67,76)(H,68,80)(H,69,77)(H,70,81)(H,71,78)(H,72,79)(H4,60,61,64)(H4,62,63,65)/t39-,40-,41-,42-,43-,44-,47-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	1.70	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226412 (CHEMBL3142332) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 Show InChI InChI=1S/C57H87N15O10S2/c1-4-82-38-24-22-35(23-25-38)29-41-50(77)69-42(28-34-14-6-5-7-15-34)52(79)72-47(33(2)3)54(81)70-43(30-45(58)73)51(78)71-44(32-83-84-57(31-46(74)66-41,36-16-8-9-17-36)37-18-10-11-19-37)53(80)68-40(21-13-27-65-56(62)63)49(76)67-39(48(59)75)20-12-26-64-55(60)61/h5-7,14-15,22-25,33,36-37,39-44,47H,4,8-13,16-21,26-32H2,1-3H3,(H2,58,73)(H2,59,75)(H,66,74)(H,67,76)(H,68,80)(H,69,77)(H,70,81)(H,71,78)(H,72,79)(H4,60,61,64)(H4,62,63,65)/t39-,40+,41+,42+,43+,44+,47+/m1/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	1.70	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226411 (CHEMBL3142329) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 Show InChI InChI=1S/C57H87N15O10S2/c1-4-82-38-24-22-35(23-25-38)29-41-50(77)69-42(28-34-14-6-5-7-15-34)52(79)72-47(33(2)3)54(81)70-43(30-45(58)73)51(78)71-44(32-83-84-57(31-46(74)66-41,36-16-8-9-17-36)37-18-10-11-19-37)53(80)68-40(21-13-27-65-56(62)63)49(76)67-39(48(59)75)20-12-26-64-55(60)61/h5-7,14-15,22-25,33,36-37,39-44,47H,4,8-13,16-21,26-32H2,1-3H3,(H2,58,73)(H2,59,75)(H,66,74)(H,67,76)(H,68,80)(H,69,77)(H,70,81)(H,71,78)(H,72,79)(H4,60,61,64)(H4,62,63,65)/t39-,40+,41-,42-,43-,44-,47-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	1.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity against sigma receptor				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226417 (CHEMBL3142331) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 |r| Show InChI InChI=1S/C51H75N11O9S2/c1-4-71-35-22-20-32(21-23-35)26-37-45(66)59-38(25-31-13-6-5-7-14-31)47(68)62-43(30(2)3)49(70)60-39(27-41(52)63)46(67)61-40(48(69)58-36(44(53)65)19-12-24-56-50(54)55)29-72-73-51(28-42(64)57-37,33-15-8-9-16-33)34-17-10-11-18-34/h5-7,13-14,20-23,30,33-34,36-40,43H,4,8-12,15-19,24-29H2,1-3H3,(H2,52,63)(H2,53,65)(H,57,64)(H,58,69)(H,59,66)(H,60,70)(H,61,67)(H,62,68)(H4,54,55,56)/t36-,37-,38-,39-,40-,43-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	2.5	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226413 (CHEMBL2369777) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 |r| Show InChI InChI=1S/C57H87N13O10S2/c1-4-80-39-25-23-36(24-26-39)30-42-51(75)67-43(29-35-15-6-5-7-16-35)53(77)70-48(34(2)3)55(79)68-44(31-46(59)71)52(76)69-45(33-81-82-57(32-47(72)64-42,37-17-8-9-18-37)38-19-10-11-20-38)54(78)66-41(22-14-28-63-56(61)62)50(74)65-40(49(60)73)21-12-13-27-58/h5-7,15-16,23-26,34,37-38,40-45,48H,4,8-14,17-22,27-33,58H2,1-3H3,(H2,59,71)(H2,60,73)(H,64,72)(H,65,74)(H,66,78)(H,67,75)(H,68,79)(H,69,76)(H,70,77)(H4,61,62,63)/t40-,41-,42+,43-,44-,45-,48-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	2.60	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (RAT)	BDBM50384444 (CHEMBL2035510) Show SMILES CC(C)C1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2cccc(F)c2c1 Show InChI InChI=1S/C21H17FN2O4/c1-11(2)21(19(26)24-20(27)28-21)15-8-9-17(23-18(15)25)13-7-6-12-4-3-5-16(22)14(12)10-13/h3-11H,1-2H3,(H,23,25)(H,24,26,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	3.16	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at rat EP3 receptor expressed in human U2OS cells co-expressing Gqi5 assessed as inhibition of PGE2-induced response after 24 hrs...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414536 (CHEMBL551202) Show SMILES Clc1cccc(Cl)c1-c1nnc(NC(=O)c2ccc3OCCOc3c2)s1 Show InChI InChI=1S/C17H11Cl2N3O3S/c18-10-2-1-3-11(19)14(10)16-21-22-17(26-16)20-15(23)9-4-5-12-13(8-9)25-7-6-24-12/h1-5,8H,6-7H2,(H,20,22,23)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	3.16	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50384444 (CHEMBL2035510) Show SMILES CC(C)C1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2cccc(F)c2c1 Show InChI InChI=1S/C21H17FN2O4/c1-11(2)21(19(26)24-20(27)28-21)15-8-9-17(23-18(15)25)13-7-6-12-4-3-5-16(22)14(12)10-13/h3-11H,1-2H3,(H,23,25)(H,24,26,27)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	3.16	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at human EP3c receptor expressed in human U2OS cells assessed as inhibition of PGE2-induced calcium mobilization after 24 hrs by ...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Vasopressin V2 receptor (Sus scrofa)	BDBM50020654 (1-[19-Benzyl-13-carbamoylmethyl-22-(4-ethoxy-benzy...) Show SMILES CCOc1ccc(C[C@H]2NC(=O)CC3(CCCCC3)SSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](Cc3ccccc3)NC2=O)C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CCCNC(N)=N)C(N)=O)cc1 Show InChI InChI=1S/C51H74N12O10S2/c1-4-73-33-19-17-32(18-20-33)26-35-44(67)59-36(25-31-13-7-5-8-14-31)46(69)62-42(30(2)3)48(71)60-37(27-40(52)64)45(68)61-38(29-74-75-51(28-41(65)57-35)21-9-6-10-22-51)49(72)63-24-12-16-39(63)47(70)58-34(43(53)66)15-11-23-56-50(54)55/h5,7-8,13-14,17-20,30,34-39,42H,4,6,9-12,15-16,21-29H2,1-3H3,(H2,52,64)(H2,53,66)(H,57,65)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,54,55,56)/t34-,35-,36-,37-,38-,39+,42+/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	3.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Compound was tested for inhibition against V2 vasopressin receptor in pig renal medullary membrane preparations.				J Med Chem 29: 2425-6 (1987) BindingDB Entry DOI: 10.7270/Q23T9G6Q
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226416 (CHEMBL2369525) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-2-[#6]-[#6]-[#6]-[#6@H]-2-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 Show InChI InChI=1S/C56H82N12O10S2/c1-4-78-38-24-22-35(23-25-38)29-40-49(72)64-41(28-34-14-6-5-7-15-34)51(74)67-47(33(2)3)53(76)65-42(30-45(57)69)50(73)66-43(32-79-80-56(31-46(70)62-40,36-16-8-9-17-36)37-18-10-11-19-37)54(77)68-27-13-21-44(68)52(75)63-39(48(58)71)20-12-26-61-55(59)60/h5-7,14-15,22-25,33,36-37,39-44,47H,4,8-13,16-21,26-32H2,1-3H3,(H2,57,69)(H2,58,71)(H,62,70)(H,63,75)(H,64,72)(H,65,76)(H,66,73)(H,67,74)(H4,59,60,61)/t39-,40+,41-,42-,43-,44-,47-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	3.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Oxytocin receptor (Homo sapiens (Human))	BDBM50372608 (CHEMBL429736 | GSK-221149A) Show SMILES CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)c2coc(C)n2)C(=O)[C@H](NC1=O)C1Cc2ccccc2C1 Show InChI InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE PC cid PC sid PDB UniChem Similars	PDB Article PubMed	4.10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Research and Development Curated by ChEMBL					Assay Description Binding affinity to recombinant oxytocin receptor				Bioorg Med Chem Lett 18: 90-4 (2008) Article DOI: 10.1016/j.bmcl.2007.11.008 BindingDB Entry DOI: 10.7270/Q2XD12H2
					More data for this Ligand-Target Pair				3D Structure (crystal)
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226414 (CHEMBL2369778) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](-[#7])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 |r| Show InChI InChI=1S/C57H87N13O10S2/c1-4-80-39-25-23-36(24-26-39)30-42-51(75)67-43(29-35-15-6-5-7-16-35)53(77)70-48(34(2)3)55(79)68-44(31-46(59)71)52(76)69-45(33-81-82-57(32-47(72)64-42,37-17-8-9-18-37)38-19-10-11-20-38)54(78)66-41(21-12-13-27-58)50(74)65-40(49(60)73)22-14-28-63-56(61)62/h5-7,15-16,23-26,34,37-38,40-45,48H,4,8-14,17-22,27-33,58H2,1-3H3,(H2,59,71)(H2,60,73)(H,64,72)(H,65,74)(H,66,78)(H,67,75)(H,68,79)(H,69,76)(H,70,77)(H4,61,62,63)/t40-,41-,42+,43-,44-,45-,48-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	4.20	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity against sigma receptor				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50384443 (CHEMBL1770317) Show SMILES CC(C)C1(OC(O)=NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 |c:6| Show InChI InChI=1S/C21H18N2O4/c1-12(2)21(19(25)23-20(26)27-21)16-9-10-17(22-18(16)24)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,1-2H3,(H,22,24)(H,23,25,26)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	5.01	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Binding affinity to human EP3				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414543 (CHEMBL550316) Show SMILES CN1CCOc2ccc(cc12)C(=O)Nc1nnc(s1)-c1c(C)cccc1C Show InChI InChI=1S/C20H20N4O2S/c1-12-5-4-6-13(2)17(12)19-22-23-20(27-19)21-18(25)14-7-8-16-15(11-14)24(3)9-10-26-16/h4-8,11H,9-10H2,1-3H3,(H,21,23,25)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	5.01	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Vasopressin V2 receptor (Sus scrofa)	BDBM50020675 (1-[13-Benzyl-7-carbamoylmethyl-16-(4-ethoxy-benzyl...) Show SMILES CCOc1ccc(C[C@H]2NC(=O)CC(CC)(CC)SSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](Cc3ccccc3)NC2=O)C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)cc1 Show InChI InChI=1S/C52H77N13O11S2/c1-6-52(7-2)27-42(68)59-35(25-32-18-20-33(21-19-32)76-8-3)45(70)61-36(24-31-14-10-9-11-15-31)47(72)64-43(30(4)5)49(74)62-37(26-40(53)66)46(71)63-38(29-77-78-52)50(75)65-23-13-17-39(65)48(73)60-34(16-12-22-57-51(55)56)44(69)58-28-41(54)67/h9-11,14-15,18-21,30,34-39,43H,6-8,12-13,16-17,22-29H2,1-5H3,(H2,53,66)(H2,54,67)(H,58,69)(H,59,68)(H,60,73)(H,61,70)(H,62,74)(H,63,71)(H,64,72)(H4,55,56,57)/t34-,35-,36-,37-,38-,39+,43+/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	5.30	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Compound was tested for inhibition against V2 vasopressin receptor in pig renal medullary membrane preparations.				J Med Chem 29: 2425-6 (1987) BindingDB Entry DOI: 10.7270/Q23T9G6Q
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483809 (CHEMBL1770337) Show SMILES CC(C)C1(OC(=O)NC1=O)c1cc(C)c([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C22H20N2O4/c1-12(2)22(20(26)24-21(27)28-22)17-10-13(3)18(23-19(17)25)16-9-8-14-6-4-5-7-15(14)11-16/h4-12H,1-3H3,(H,23,25)(H,24,26,27)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	6.30	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50384445 (CHEMBL2035508) Show SMILES CC(C)C1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2n(C)ccc2c1 Show InChI InChI=1S/C20H19N3O4/c1-11(2)20(18(25)22-19(26)27-20)14-5-6-15(21-17(14)24)12-4-7-16-13(10-12)8-9-23(16)3/h4-11H,1-3H3,(H,21,24)(H,22,25,26)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	6.31	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at human EP3c receptor expressed in human U2OS cells assessed as inhibition of PGE2-induced calcium mobilization after 24 hrs by ...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (RAT)	BDBM50414549 (CHEMBL563480) Show SMILES CCN1CCOc2ccc(cc12)C(=O)Nc1nnc(s1)-c1c(Cl)cccc1Cl Show InChI InChI=1S/C19H16Cl2N4O2S/c1-2-25-8-9-27-15-7-6-11(10-14(15)25)17(26)22-19-24-23-18(28-19)16-12(20)4-3-5-13(16)21/h3-7,10H,2,8-9H2,1H3,(H,22,24,26)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	6.31	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Inhibition of rat EP3 receptor				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50417191 (CHEMBL1272136) Show SMILES CCc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1 Show InChI InChI=1S/C21H19ClFN3O2/c1-2-14-6-3-7-15(12-14)24-21(28)25-19-10-5-11-26(20(19)27)13-16-17(22)8-4-9-18(16)23/h3-12H,2,13H2,1H3,(H2,24,25,28)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	6.31	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in human U2OS cells assessed as inhibition of PGE2-induced intracellular calcium mobilization by ...				Bioorg Med Chem Lett 20: 6744-7 (2010) Article DOI: 10.1016/j.bmcl.2010.08.137 BindingDB Entry DOI: 10.7270/Q25M65Z8
					More data for this Ligand-Target Pair
Vasopressin V2 receptor (Sus scrofa)	BDBM50020653 (1-[19-Benzyl-13-carbamoylmethyl-22-(4-ethoxy-benzy...) Show SMILES CCOc1ccc(C[C@H]2NC(=O)CC3(CCCCC3)SSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](Cc3ccccc3)NC2=O)C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)cc1 Show InChI InChI=1S/C53H77N13O11S2/c1-4-77-34-19-17-33(18-20-34)26-36-46(71)62-37(25-32-13-7-5-8-14-32)48(73)65-44(31(2)3)50(75)63-38(27-41(54)67)47(72)64-39(30-78-79-53(28-43(69)60-36)21-9-6-10-22-53)51(76)66-24-12-16-40(66)49(74)61-35(15-11-23-58-52(56)57)45(70)59-29-42(55)68/h5,7-8,13-14,17-20,31,35-40,44H,4,6,9-12,15-16,21-30H2,1-3H3,(H2,54,67)(H2,55,68)(H,59,70)(H,60,69)(H,61,74)(H,62,71)(H,63,75)(H,64,72)(H,65,73)(H4,56,57,58)/t35-,36-,37-,38-,39-,40+,44+/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	6.40	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Compound was tested for inhibition against V2 vasopressin receptor in pig renal medullary membrane preparations.				J Med Chem 29: 2425-6 (1987) BindingDB Entry DOI: 10.7270/Q23T9G6Q
					More data for this Ligand-Target Pair
Adenylate cyclase type 4 (Homo sapiens (Human))	BDBM50226418 (CHEMBL3142313) Show SMILES [#6]-[#6]-[#8]-c1ccc(-[#6]-[#6@@H]-2-[#7]-[#6](=O)-[#6]C([#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c3ccccc3)-[#7]-[#6]-2=O)-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](-[#8])=O)([#6]-2-[#6]-[#6]-[#6]-[#6]-2)[#6]-2-[#6]-[#6]-[#6]-[#6]-2)cc1 |r| Show InChI InChI=1S/C57H86N14O11S2/c1-4-82-38-24-22-35(23-25-38)29-41-49(75)68-42(28-34-14-6-5-7-15-34)51(77)71-47(33(2)3)53(79)69-43(30-45(58)72)50(76)70-44(32-83-84-57(31-46(73)65-41,36-16-8-9-17-36)37-18-10-11-19-37)52(78)66-39(20-12-26-63-55(59)60)48(74)67-40(54(80)81)21-13-27-64-56(61)62/h5-7,14-15,22-25,33,36-37,39-44,47H,4,8-13,16-21,26-32H2,1-3H3,(H2,58,72)(H,65,73)(H,66,78)(H,67,74)(H,68,75)(H,69,79)(H,70,76)(H,71,77)(H,80,81)(H4,59,60,63)(H4,61,62,64)/t39-,40-,41-,42-,43-,44-,47-/m0/s1	UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	7.80	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Research and Development Division Curated by ChEMBL					Assay Description Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone				J Med Chem 30: 2291-4 (1987) BindingDB Entry DOI: 10.7270/Q2MG7RRN
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483823 (CHEMBL1770341) Show SMILES CC(C)[C@]1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 |r| Show InChI InChI=1S/C21H18N2O4/c1-12(2)21(19(25)23-20(26)27-21)16-9-10-17(22-18(16)24)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,1-2H3,(H,22,24)(H,23,25,26)/t21-/m0/s1	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid UniChem	Article PubMed	7.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483821 (CHEMBL1770320) Show SMILES O=C1NC(=O)C(O1)(C1CCCCC1)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C24H22N2O4/c27-21-19(24(18-8-2-1-3-9-18)22(28)26-23(29)30-24)12-13-20(25-21)17-11-10-15-6-4-5-7-16(15)14-17/h4-7,10-14,18H,1-3,8-9H2,(H,25,27)(H,26,28,29)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	7.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483814 (CHEMBL1770319) Show SMILES O=C1NC(=O)C(O1)(C1CCCC1)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C23H20N2O4/c26-20-18(23(17-7-3-4-8-17)21(27)25-22(28)29-23)11-12-19(24-20)16-10-9-14-5-1-2-6-15(14)13-16/h1-2,5-6,9-13,17H,3-4,7-8H2,(H,24,26)(H,25,27,28)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	7.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (RAT)	BDBM50384445 (CHEMBL2035508) Show SMILES CC(C)C1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2n(C)ccc2c1 Show InChI InChI=1S/C20H19N3O4/c1-11(2)20(18(25)22-19(26)27-20)14-5-6-15(21-17(14)24)12-4-7-16-13(10-12)8-9-23(16)3/h4-11H,1-3H3,(H,21,24)(H,22,25,26)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	7.94	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at rat EP3 receptor expressed in human U2OS cells co-expressing Gqi5 assessed as inhibition of PGE2-induced response after 24 hrs...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414548 (CHEMBL550055) Show SMILES Clc1cccc(Cl)c1-c1nnc(NC(=O)c2ccc3OCCNc3c2)s1 Show InChI InChI=1S/C17H12Cl2N4O2S/c18-10-2-1-3-11(19)14(10)16-22-23-17(26-16)21-15(24)9-4-5-13-12(8-9)20-6-7-25-13/h1-5,8,20H,6-7H2,(H,21,23,24)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	7.94	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Vasopressin V2 receptor (Sus scrofa)	BDBM50020674 (1-[13-Benzyl-7-carbamoylmethyl-16-(4-ethoxy-benzyl...) Show SMILES CCOc1ccc(C[C@H]2NC(=O)CC(CC)(CC)SSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](Cc3ccccc3)NC2=O)C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CCCNC(N)=N)C(N)=O)cc1 Show InChI InChI=1S/C50H74N12O10S2/c1-6-50(7-2)27-40(64)56-34(25-31-18-20-32(21-19-31)72-8-3)43(66)58-35(24-30-14-10-9-11-15-30)45(68)61-41(29(4)5)47(70)59-36(26-39(51)63)44(67)60-37(28-73-74-50)48(71)62-23-13-17-38(62)46(69)57-33(42(52)65)16-12-22-55-49(53)54/h9-11,14-15,18-21,29,33-38,41H,6-8,12-13,16-17,22-28H2,1-5H3,(H2,51,63)(H2,52,65)(H,56,64)(H,57,69)(H,58,66)(H,59,70)(H,60,67)(H,61,68)(H4,53,54,55)/t33-,34-,35-,36-,37-,38+,41+/m1/s1	Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	8.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Compound was tested for inhibition against V2 vasopressin receptor in pig renal medullary membrane preparations.				J Med Chem 29: 2425-6 (1987) BindingDB Entry DOI: 10.7270/Q23T9G6Q
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50384443 (CHEMBL1770317) Show SMILES CC(C)C1(OC(O)=NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 |c:6| Show InChI InChI=1S/C21H18N2O4/c1-12(2)21(19(25)23-20(26)27-21)16-9-10-17(22-18(16)24)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,1-2H3,(H,22,24)(H,23,25,26)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at human EP3c receptor expressed in human U2OS cells assessed as inhibition of PGE2-induced calcium mobilization after 24 hrs by ...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (RAT)	BDBM50384443 (CHEMBL1770317) Show SMILES CC(C)C1(OC(O)=NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 |c:6| Show InChI InChI=1S/C21H18N2O4/c1-12(2)21(19(25)23-20(26)27-21)16-9-10-17(22-18(16)24)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,1-2H3,(H,22,24)(H,23,25,26)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at rat EP3 receptor expressed in human U2OS cells co-expressing Gqi5 assessed as inhibition of PGE2-induced response after 24 hrs...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50384443 (CHEMBL1770317) Show SMILES CC(C)C1(OC(O)=NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 |c:6| Show InChI InChI=1S/C21H18N2O4/c1-12(2)21(19(25)23-20(26)27-21)16-9-10-17(22-18(16)24)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,1-2H3,(H,22,24)(H,23,25,26)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Oxytocin receptor (Homo sapiens (Human))	BDBM50177595 ((2S)-5-amino-2-{[(2S)-1-{[(4R,7S,10S,13S,16R)-13-[...) Show SMILES CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |r| Show InChI InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE PC cid PC sid UniChem Patents Similars	Article PubMed	11	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Research and Development Curated by ChEMBL					Assay Description Binding affinity to human oxytocin receptor				Bioorg Med Chem Lett 18: 90-4 (2008) Article DOI: 10.1016/j.bmcl.2007.11.008 BindingDB Entry DOI: 10.7270/Q2XD12H2
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414537 (CHEMBL554297) Show SMILES COc1cc(Cl)c(-c2nnc(NC(=O)c3ccc4OCCOc4c3)s2)c(Cl)c1 Show InChI InChI=1S/C18H13Cl2N3O4S/c1-25-10-7-11(19)15(12(20)8-10)17-22-23-18(28-17)21-16(24)9-2-3-13-14(6-9)27-5-4-26-13/h2-3,6-8H,4-5H2,1H3,(H,21,23,24)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	12.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414533 (CHEMBL549437) Show SMILES Cc1cccc(C)c1-c1nnc(NC(=O)c2ccc3OCCOc3c2)s1 Show InChI InChI=1S/C19H17N3O3S/c1-11-4-3-5-12(2)16(11)18-21-22-19(26-18)20-17(23)13-6-7-14-15(10-13)25-9-8-24-14/h3-7,10H,8-9H2,1-2H3,(H,20,22,23)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	12.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (RAT)	BDBM50384446 (CHEMBL2035509) Show SMILES CC(C)C1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc(C)c(C)c1 Show InChI InChI=1S/C19H20N2O4/c1-10(2)19(17(23)21-18(24)25-19)14-7-8-15(20-16(14)22)13-6-5-11(3)12(4)9-13/h5-10H,1-4H3,(H,20,22)(H,21,23,24)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	12.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at rat EP3 receptor expressed in human U2OS cells co-expressing Gqi5 assessed as inhibition of PGE2-induced response after 24 hrs...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414544 (CHEMBL562329) Show SMILES CN1CCOc2cc(ccc12)C(=O)Nc1nnc(s1)-c1c(C)cccc1C Show InChI InChI=1S/C20H20N4O2S/c1-12-5-4-6-13(2)17(12)19-22-23-20(27-19)21-18(25)14-7-8-15-16(11-14)26-10-9-24(15)3/h4-8,11H,9-10H2,1-3H3,(H,21,23,25)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	15.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483827 (CHEMBL1770322) Show SMILES O=C1NC(=O)C(Cc2ccccc2)(O1)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C25H18N2O4/c28-22-20(25(23(29)27-24(30)31-25)15-16-6-2-1-3-7-16)12-13-21(26-22)19-11-10-17-8-4-5-9-18(17)14-19/h1-14H,15H2,(H,26,28)(H,27,29,30)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	16	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50384446 (CHEMBL2035509) Show SMILES CC(C)C1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc(C)c(C)c1 Show InChI InChI=1S/C19H20N2O4/c1-10(2)19(17(23)21-18(24)25-19)14-7-8-15(20-16(14)22)13-6-5-11(3)12(4)9-13/h5-10H,1-4H3,(H,20,22)(H,21,23,24)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	19.9	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA Curated by ChEMBL					Assay Description Antagonist activity at human EP3c receptor expressed in human U2OS cells assessed as inhibition of PGE2-induced calcium mobilization after 24 hrs by ...				ACS Med Chem Lett 1: 316-320 (2010) Article DOI: 10.1021/ml100077x BindingDB Entry DOI: 10.7270/Q2BG2Q1F
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414534 (CHEMBL564190) Show SMILES Cc1cc(C)c(-c2nnc(NC(=O)c3ccc4OCCOc4c3)s2)c(C)c1 Show InChI InChI=1S/C20H19N3O3S/c1-11-8-12(2)17(13(3)9-11)19-22-23-20(27-19)21-18(24)14-4-5-15-16(10-14)26-7-6-25-15/h4-5,8-10H,6-7H2,1-3H3,(H,21,23,24)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	19.9	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483811 (CHEMBL1770340) Show SMILES CC(C)[C@@]1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 |r| Show InChI InChI=1S/C21H18N2O4/c1-12(2)21(19(25)23-20(26)27-21)16-9-10-17(22-18(16)24)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,1-2H3,(H,22,24)(H,23,25,26)/t21-/m1/s1	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid UniChem	Article PubMed	20	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483812 (CHEMBL1770316) Show SMILES CC1(OC(=O)NC1=O)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C19H14N2O4/c1-19(17(23)21-18(24)25-19)14-8-9-15(20-16(14)22)13-7-6-11-4-2-3-5-12(11)10-13/h2-10H,1H3,(H,20,22)(H,21,23,24)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	20	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50329821 (1-(1-(2-chloro-6-fluorobenzyl)-2-oxo-1,2-dihydropy...) Show SMILES COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1 Show InChI InChI=1S/C20H17ClFN3O3/c1-28-14-6-2-5-13(11-14)23-20(27)24-18-9-4-10-25(19(18)26)12-15-16(21)7-3-8-17(15)22/h2-11H,12H2,1H3,(H2,23,24,27)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in human U2OS cells assessed as inhibition of PGE2-induced intracellular calcium mobilization by ...				Bioorg Med Chem Lett 20: 6744-7 (2010) Article DOI: 10.1016/j.bmcl.2010.08.137 BindingDB Entry DOI: 10.7270/Q25M65Z8
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50414542 (CHEMBL562994) Show SMILES Cc1cccc(C)c1-c1nnc(NC(=O)c2ccc3CCCCc3c2)s1 Show InChI InChI=1S/C21H21N3OS/c1-13-6-5-7-14(2)18(13)20-23-24-21(26-20)22-19(25)17-11-10-15-8-3-4-9-16(15)12-17/h5-7,10-12H,3-4,8-9H2,1-2H3,(H,22,24,25)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem	Article PubMed	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Pharmaceuticals Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in cells assessed as mobilization of intracellular calcium by FLIPR assay				Bioorg Med Chem Lett 19: 4292-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.074 BindingDB Entry DOI: 10.7270/Q2SQ90DS
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483815 (CHEMBL1770321) Show SMILES O=C1NC(=O)C(O1)(c1ccccc1)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C24H16N2O4/c27-21-19(24(18-8-2-1-3-9-18)22(28)26-23(29)30-24)12-13-20(25-21)17-11-10-15-6-4-5-7-16(15)14-17/h1-14H,(H,25,27)(H,26,28,29)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	32	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Oxytocin receptor (Homo sapiens (Human))	BDBM50177595 ((2S)-5-amino-2-{[(2S)-1-{[(4R,7S,10S,13S,16R)-13-[...) Show SMILES CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |r| Show InChI InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE PC cid PC sid UniChem Patents Similars	Article PubMed	32	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Research and Development Curated by ChEMBL					Assay Description Binding affinity to recombinant oxytocin receptor				Bioorg Med Chem Lett 18: 90-4 (2008) Article DOI: 10.1016/j.bmcl.2007.11.008 BindingDB Entry DOI: 10.7270/Q2XD12H2
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483818 (CHEMBL1770328) Show SMILES CC1(CNC(=O)N1)c1ccc([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C19H17N3O2/c1-19(11-20-18(24)22-19)15-8-9-16(21-17(15)23)14-7-6-12-4-2-3-5-13(12)10-14/h2-10H,11H2,1H3,(H,21,23)(H2,20,22,24)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	40	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human))	BDBM50483808 (CHEMBL1770336) Show SMILES CC(C)C1(OC(=O)NC1=O)c1cc(Br)c([nH]c1=O)-c1ccc2ccccc2c1 Show InChI InChI=1S/C21H17BrN2O4/c1-11(2)21(19(26)24-20(27)28-21)15-10-16(22)17(23-18(15)25)14-8-7-12-5-3-4-6-13(12)9-14/h3-11H,1-2H3,(H,23,25)(H,24,26,27)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	40	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
GlaxoSmithKline Curated by ChEMBL					Assay Description Antagonist activity at human EP3 receptor expressed in CHO cells assessed as inhibition of PGE2-induced increase in intracellular calcium concentrati...				Bioorg Med Chem Lett 21: 2806-11 (2011) Article DOI: 10.1016/j.bmcl.2011.03.107 BindingDB Entry DOI: 10.7270/Q2NZ8BGM
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 213 total )  |  Next  |  Last  >>

Jump to: